Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background The most suitable antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients.Methods As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment. Mean age of patients was 67 years (SD 7) and mean blood pressure 177/96 mm Hg (14/10) after placebo run-in. We followed up patients for at least 4 years (mean 4.7 years [1.1]). We used Cox regression analysis with baseline Framingham risk score and electrocardiogram-LVH as covariates to compare the effects of the drugs on the primary composite endpoint of cardiovascular morbidity and mortality (cardiovascular death, stroke, or myocardial infarction).Findings Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients. The primary endpoint occurred in 103 patients assigned losartan (n=586) and 139 assigned atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), p=0.031. 38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p=0.028. Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p=0.002.Interpretation Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All available BP-lowering drugs can be used, but evidence strongly supports using a renin-angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in patients with evidence of end-organ damage (albuminuria and left ventricular [LV] hypertrophy).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [213]
In the citing paper
“In patients with congestive heart failure (CHF), including diabetic subgroups, ARBs have been shown to reduce major CVD outcomes (175–178), and in type 2 patients with significant nephropathy, ARBs were superior to calcium channel blockers for reducing heart failure (179–181).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [178]
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Self-citationDahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
(2000) · PubMed · Cited by 2,095
Research works printed but not linked: 2
- Liu, 2000, Cardiovascular disease and prognosis in adults with glucose disorders: the Strong Heart Study, J Am Coll Cardiol, 35, 263A
- 2002, Diabetic nephropathy, Diabetes Care, 25, S85
Cited by
Items 101–200 of 1,001
Khan, N. A., Hemmelgarn, B., Padwal, R., Larochelle, P., Mahon, J. L., Lewanczuk, R. Z., McAlister, F. A., Rabkin, S. W., Hill, M. D., Feldman, R. D., et al. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70798-5 · Cited by 246
McFarlane, S. I., Kumar, A., & Sowers, J. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00432-6 · Cited by 245
Westphal, M., Ylä-Herttuala, S., Martin, J., Warnke, P., Menei, P., Eckland, D., Kinley, J., Kay, R., & Ram, Z. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70274-2 · Cited by 241
Ferrario, C. M. (2006) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2006.003 · Cited by 240
The Task Force on diabetes, P.-D. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236
Insulin resistance and the endothelium
Hsueh, W. A., Lyon, C. J., & Quiñones, M. J. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.042 · Cited by 229
Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N., & Tegegne, G. G. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft515 · Cited by 232
“A randomized trial comparing losartan with atenolol in hypertensive patients with left ventricular hypertrophy (not on dialysis) has earlier demonstrated that losartan was superior to atenolol therapy in preventing strokes, myocardial infarctions and cardiovascular death [9].”
8. Cardiovascular Disease and Risk Management
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s011 · Cited by 233
Disorders of Hemostasis Associated with Chronic Kidney Disease
Jalal, D., Chonchol, M., & Targher, G. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1248722 · Cited by 231
Diabetes, left ventricular systolic dysfunction, and chronic heart failure
MacDonald, M. R., Petrie, M. C., Hawkins, N. M., Petrie, J. R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., & McMurray, J. J. V. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn156 · Cited by 227
Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes*
Mogensen, C. E. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01157.x · Cited by 227
The Relationship between Lung Inflammation and Cardiovascular Disease
Van Eeden, S., Leipsic, J., Paul Man, S. F., & Sin, D. D. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0455pp · Cited by 226
Norris, S. L., Kansagara, D., Bougatsos, C., & Fu, R. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-11-200806030-00008 · Cited by 228
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 220
Large and Small Artery Cross-Talk and Recent Morbidity-Mortality Trials in Hypertension
Laurent, S., Briet, M., & Boutouyrie, P. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.133116 · Cited by 217
Yusuf, S., Ostergren, J. B., Gerstein, H. C., Pfeffer, M. A., Swedberg, K., Granger, C. B., Olofsson, B., Probstfield, J., & McMurray, J. V. (2005) · Circulation · doi:10.1161/circulationaha.104.528166 · Cited by 215
Voulgari, Tentolouris, N., & Papadogiannis, D. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s11681 · Cited by 210
Hypertension management in patients with cardiovascular comorbidities
Lauder, L., Mahfoud, F., Azizi, M., Bhatt, D. L., Ewen, S., Kario, K., Parati, G., Rossignol, P., Schlaich, M. P., Teo, K. K., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac395 · Cited by 210
Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view
Zimmet, P., Shaw, J., & Alberti, K. G. M. M. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01052.x · Cited by 208
Ikramuddin, S., Billington, C. J., Lee, W.-J., Bantle, J. P., Thomas, A. J., Connett, J. E., Leslie, D. B., Inabnet, W. B., Jeffery, R. W., Chong, K., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00089-3 · Cited by 207
Dandona, P., Kumar, V., Aljada, A., Ghanim, H., Syed, T., Hofmayer, D., Mohanty, P., Tripathy, D., & Garg, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021836 · Cited by 207
Cardiac GPCRs: GPCR signaling in healthy and failing hearts
Salazar, N. C., Chen, J., & Rockman, H. A. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.02.010 · Cited by 205
Thomopoulos, C., Parati, G., & Zanchetti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001276 · Cited by 206
“Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol.”
Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
Newman, J. D., Schwartzbard, A. Z., Weintraub, H. S., Goldberg, I. J., & Berger, J. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.001 · Cited by 205
Insulin Resistance and Atherosclerosis
Razani, B., Chakravarthy, M. V., & Semenkovich, C. F. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.05.001 · Cited by 199
Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis
Candido, R., Allen, T. J., Lassila, M., Cao, Z., Thallas, V., Cooper, M. E., & Jandeleit-Dahm, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000124061.78478.94 · Cited by 195
The renin-angiotensin system and diabetes: an update.
Ribeiro‐Oliveira, A., Nogueira, A. I., Pereira, R. M., Boas, W. W. V., Santos, R. A. S., & Silva, A. C. S. E. (2008) · PubMed Central · Cited by 193
Assessment and Management of Hypertension in Transplant Patients
Weir, M. R., Burgess, E. D., Cooper, J. E., Fenves, A. Z., Goldsmith, D., McKay, D., Mehrotra, A., Mitsnefes, M. M., Sica, D. A., & Taler, S. J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014080834 · Cited by 190
Raebel, M. A. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00258.x · Cited by 188
Cardiovascular drug therapy in the elderly: benefits and challenges
Fleg, J. L., Aronow, W. S., & Frishman, W. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.162 · Cited by 186
Bangalore, S., Fakheri, R., Toklu, B., & Messerli, F. H. (2016) · BMJ · doi:10.1136/bmj.i438 · Cited by 183
Gram Negative Wound Infection in Hospitalised Adult Burn Patients-Systematic Review and Metanalysis-
Azzopardi, E. A., Azzopardi, E., Camilleri, L., Villapalos, J., Boyce, D. E., Dziewulski, P., Dickson, W. A., & Whitaker, I. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095042 · Cited by 183
“Pre-validated critical appraisal tools were employed on the primary research to achieve significant depth of appraisal [12,18].”
Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome
Prasad, A., & Quyyumi, A. A. (2004) · Circulation · doi:10.1161/01.cir.0000141736.76561.78 · Cited by 178
Diabetic Nephropathy: Can Renoprotection Be Extrapolated to Cardiovascular Protection?
Opie, L. H., & Parving, H.-H. (2002) · Circulation · doi:10.1161/01.cir.0000028099.24188.c4 · Cited by 178
Opelz, G., Zeier, M., Laux, G., Morath, C., & Döhler, B. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050543 · Cited by 177
Coronary Heart Disease in Patients With Diabetes
Berry, C., Tardif, J.-C., & Bourassa, M. G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.046 · Cited by 168
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s61438 · Cited by 168
Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
Fonseca, V., Desouza, C., Asnani, S., & Jialal, I. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0034 · Cited by 168
Kim, H.-L., Lee, E. M., Ahn, S. Y., Kim, K.-I., Kim, H. C., Kim, J. H., Lee, H.-Y., Lee, J. H., Park, J.-M., Cho, E. J., et al. (2023) · Clinical Hypertension · doi:10.1186/s40885-023-00234-9 · Cited by 164
Population based screening for chronic kidney disease: cost effectiveness study
Manns, B., Hemmelgarn, B., Tonelli, M., Au, F., Chiasson, T. C., Dong, J., Klarenbach, S., & on behalf of the Alberta Kidney Disease Network (2010) · BMJ · doi:10.1136/bmj.c5869 · Cited by 161
McMurray, J., Solomon, S., Pieper, K., Reed, S., Rouleau, J., Velazquez, E., White, H., Howlett, J., Swedberg, K., Maggioni, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.055 · Cited by 159
Demographics and concomitant disorders in heart failure
Krum, H., & Gilbert, R. E. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13869-x · Cited by 159
Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction
Anderson, T. J. (2003) · Heart Failure Reviews · doi:10.1023/a:1022199021949 · Cited by 193
Mancia, G., Brown, M., Castaigne, A., de Leeuw, P., Palmer, C. R., Rosenthal, T., Wagener, G., & Ruilope, L. M. (2003) · Hypertension · doi:10.1161/01.hyp.0000057420.27692.ad · Cited by 157
Old antihypertensives and new diabetes
Opie, L. H., & Schall, R. (2004) · Journal of Hypertension · doi:10.1097/01.hjh.0000133732.24501.9e · Cited by 156
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G. L., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C. S., et al. (2011) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2011.06.001 · Cited by 184
Self-citationLaparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35
DePaula, A. L., Macedo, A. L. V., Rassi, N., Machado, C. A., Schraibman, V., Silva, L. Q., & Halpern, A. (2007) · Surgical Endoscopy · doi:10.1007/s00464-007-9472-9 · Cited by 170
Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients
Chen, S.-C., & Tseng, C.-H. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.88 · Cited by 152
Guidelines for Improving the Care of the Older Person with Diabetes Mellitus
Ickowicz, E. (2003) · Cited by 152
Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?
Reusch, J. E. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19902 · Cited by 153
Regeneration of the Heart in Diabetes by Selective Copper Chelation
Cooper, G. J. S., Phillips, A. R. J., Choong, S. Y., Leonard, B. L., Crossman, D. J., Brunton, D. H., Saafi, ’. L., Dissanayake, A. M., Cowan, B. R., Young, A. A., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2501 · Cited by 151
Coronary Heart Disease in Patients With Diabetes
Berry, C., Tardif, J., & Bourassa, M. G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.045 · Cited by 164
Backer, G. D., Ambrosio, G., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · PubMed · doi:10.1097/01.hjr.0000087913.96265.e2 · Cited by 149
The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications
COOPER, M. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.004 · Cited by 147
Benvenuto, L. J., & Krakoff, L. R. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2010.146 · Cited by 147
Proteinuria and its relation to cardiovascular disease
Delles, C., & Currie, G. E. (2013) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40522 · Cited by 165
Bloomgarden, Z. T. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.933 · Cited by 142
Struthers, A. D., & Morris, A. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08358-7 · Cited by 144
Zelmanovitz, T., Gerchman, F., Balthazar, A. P., Thomazelli, F. C. S., de Matos, J. D., & Canani, L. H. S. (2009) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-1-10 · Cited by 184
Rachmani, R., Slavachevsky, I., Amit, M., Levi, Z., Kedar, Y., Berla, M., & Ravid, M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01194.x · Cited by 142
RetractedApproaches to prevention of cardiovascular complications and events in diabetes mellitus
Coccheri, S. (2007) · Drugs · doi:10.2165/00003495-200767070-00005 · Cited by 139
Beta-blockers for hypertension
Wiysonge, C. S. U., Bradley, H. A., Mayosi, B. M., Maroney, R. T., Mbewu, A., Opie, L., & Volmink, J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub2 · Cited by 140
Siam, N. H., Snigdha, N. N., Tabasumma, N., & Parvin, I. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2512436 · Cited by 219
Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart
Lim, H. S., MacFadyen, R. J., & Lip, G. Y. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.16.1737 · Cited by 138
Hurst, R. T., & Lee, R. W. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00010 · Cited by 139
Ibsen, H., Wachtell, K., Olsen, M. H., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahl??f, B., Devereux, R. B., de Faire, U., Fyhrquist, F., et al. (2004) · Journal of Hypertension · doi:10.1097/00004872-200409000-00026 · Cited by 137
Self-citationAkbari, A., Swedko, P. J., Clark, H. D., Hogg, W., Lemelin, J., Magner, P. O. C., Moore, L. C., & Ooi, D. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.16.1788 · Cited by 153
Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?
Sharma, A. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000132568.71409.a2 · Cited by 136
IDRIS, I. R., Thomson, G., & Sharma, J. C. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00682.x · Cited by 157
Zanchetti, A., & Ruilope, L. M. (2002) · Journal of Hypertension · doi:10.1097/00004872-200211000-00001 · Cited by 135
Li, Y., Gonzalez, P., & Zhang, L. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.05.010 · Cited by 132
Development of heart failure in recent hypertension trials
Tocci, G., Sciarretta, S., & Volpe, M. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282fe1d3d · Cited by 131
Lip, G. Y. H., Barnett, A. H., Bradbury, A. W., Cappuccio, F. P., Gill, P. S., Hughes, E. A., Imray, C., Jolly, K. B., & Patel, K. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002126 · Cited by 149
Prevention of depression in older age
Almeida, O. P. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.03.005 · Cited by 154
Vascular and cardiac benefits of angiotensin receptor blockers
Schiffrin, E. L. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01241-x · Cited by 142
Wilcox, R., Kupfer, S., & Erdmann, E. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.11.029 · Cited by 138
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy
Julius, S., Alderman, M. H., Beevers, G., Dahlöf, B., Devereux, R. B., Douglas, J. G., Edelman, J. M., Harris, K. E., Kjeldsen, S. E., Nesbitt, S. D., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.029 · Cited by 132
Self-citationCoelho‐Filho, O. R., Shah, R. V., Mitchell, R. N., Neilan, T. G., Moreno, H., Simonson, B., Kwong, R. K., Rosenzweig, A., Das, S., & Jerosch‐Herold, M. (2013) · Circulation · doi:10.1161/circulationaha.112.000438 · Cited by 146
Tissue renin angiotensin systems
Ré, R. N. (2004) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00124-x · Cited by 132
Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study
Bakris, G. L., Gaxiola, E., Messerli, F. H., Mancia, G., Erdine, S., Cooper-DeHoff, R., & Pepine, C. J. (2004) · Hypertension · doi:10.1161/01.hyp.0000143851.23721.26 · Cited by 126
Epidemiology of Cardiovascular Disease in Type 2 Diabetes: The Indian Scenario
Mohan, V., Venkatraman, J. V., & Pradeepa, R. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400121 · Cited by 144
The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes Mellitus
Snow, V., Weiss, K. B., Mottur-Pilson, C., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-7-200304010-00017 · Cited by 126
Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure
Aronow, W. S. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000175289.87583.e5 · Cited by 142
Davies, J. I., Band, M. M., Morris, A. D., & Struthers, A. D. (2004) · Diabetologia · doi:10.1007/s00125-004-1510-8 · Cited by 131
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 150
Saito, M., Khan, F., Stoklosa, T., Iannaccone, A., Negishi, K., & Marwick, T. H. (2016) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2015.09.027 · Cited by 129
Hypertension and Stroke: Epidemiological Aspects and Clinical Evaluation
Pistoia, F., Sacco, S., Degan, D., Tiseo, C., Ornello, R., & Carolei, A. (2015) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-015-0115-2 · Cited by 147
Burnier, M., & Zanchi, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000191244.91314.9d · Cited by 129
Stroke in patients with diabetes mellitus
Mankovsky, B. N., & Ziegler, D. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.490 · Cited by 122
Nagata, M., Ninomiya, T., Doi, Y., Yonemoto, K., Kubo, M., Hata, J., Tsuruya, K., Iida, M., & Kiyohara, Y. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq062 · Cited by 146
Östergren, J., Poulter, N. R., Sever, P. S., Dahlöf, B., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., et al. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328310e0d9 · Cited by 116
Self-citationRecommendations for special populations: diabetes mellitus and the metabolic syndrome
Sowers, J. R. (2003) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.07.009 · Cited by 120
Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001971 · Cited by 109
Diabetes and Hypertension: Pathogenesis, Prevention and Treatment
Landsberg, L., & Molitch, M. E. (2004) · Clinical and Experimental Hypertension · doi:10.1081/ceh-200031945 · Cited by 132
The Management of Hypertension in African Americans
Ferdinand, K. C., & Armani, A. M. (2007) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0b013e318053da59 · Cited by 112
Martin, J. H., Kelly, D. J., Mifsud, S., ZHANG, Y., COX, A., See, F. H. W., Krum, H., Wilkinson‐Berka, J. L., & Gilbert, R. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.10.041 · Cited by 116
Ibsen, H., Olsen, M. H., Wachtell, K., Borch‐Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlöf, B., Snapinn, S. M., Wan, Y., & Lyle, P. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1724 · Cited by 117
Self-citationHarris, R., Donahue, K., Rathore, S. S., Frame, P., Woolf, S. H., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00015 · Cited by 113
de Zeeuw, D., Ramjit, D. R., Zhang, Z., Ribeiro, A. B., Kurokawa, K., Lash, J. P., Chan, J. C. N., Remuzzi, G., Brenner, B. M., & Shahinfar, S. (2006) · Kidney International · doi:10.1038/sj.ki.5000326 · Cited by 141
Metadata
- Authors
- Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., & Snapinn, S.
- Affiliations
- University Hospital of Umeå (SE)
- Glostrup Hospital (DK)
- Sahlgrenska University Hospital (SE)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- University of Michigan (US)
- Oslo University Hospital (NO)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lindholm, Lars H
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 1004-1010
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1982920623
- Cited by
- 1,560
- References
- 31
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 15 · 2022: 17 · 2021: 18 · 2020: 29 · 2019: 16 · 2018: 28 · 2017: 40 · 2016: 40 · 2015: 41 · 2014: 48 · 2013: 58 · 2012: 58
- FWCI
- 129.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- losartan, atenolol, hypertension, diabetes mellitus, left ventricular hypertrophy, cardiovascular morbidity, cardiovascular mortality, antihypertensive drugs, ACE inhibitors, beta-blockers, LIFE trial, stroke, myocardial infarction, all-cause mortality, blood pressure reduction, Framingham risk score, electrocardiogram
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Regression Analysis, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.